Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Part I: Milestones in personalised medicine--imatinib.

Literature DB >> 18510992

Part I: Milestones in personalised medicine--imatinib.

Carlo Gambacorti-Passerini¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2008 PMID： 18510992 DOI： 10.1016/S1470-2045(08)70152-9

Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

1. Dynamics of targeted cancer therapy.

Authors: Ivana Bozic; Benjamin Allen; Martin A Nowak
Journal: Trends Mol Med Date: 2012-05-15 Impact factor: 11.951

2. Optical, structural and thermodynamic studies of the association of an anti-leucamic drug imatinib mesylate with transport protein.

Authors: Ashwini H Hegde; Reeta Punith; J Seetharamappa
Journal: J Fluoresc Date: 2011-09-27 Impact factor: 2.217

Review 3. A review on various targeted anticancer therapies.

Authors: Junjie Li; Feng Chen; Marlein Miranda Cona; Yuanbo Feng; Uwe Himmelreich; Raymond Oyen; Alfons Verbruggen; Yicheng Ni
Journal: Target Oncol Date: 2012-02-15 Impact factor: 4.493

4. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study.

Authors: Marc Maynadié; Roberta De Angelis; Rafael Marcos-Gragera; Otto Visser; Claudia Allemani; Carmen Tereanu; Riccardo Capocaccia; Adriano Giacomin; Jean-Michel Lutz; Carmen Martos; Risto Sankila; Tom Børge Johannesen; Arianna Simonetti; Milena Sant
Journal: Haematologica Date: 2012-09-14 Impact factor: 9.941

Part I: Milestones in personalised medicine--imatinib.

1. Dynamics of targeted cancer therapy.

2. Optical, structural and thermodynamic studies of the association of an anti-leucamic drug imatinib mesylate with transport protein.

Review 3. A review on various targeted anticancer therapies.

4. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study.

5. Potential therapies for anaplastic lymphoma kinase-driven tumors in children: progress to date.

6. Bioinformatics challenges for personalized medicine.

7. Drug discovery prospect from untapped species: indications from approved natural product drugs.

8. In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.

Review 9. Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms.

10. Advent of CRISPR Based Immunotherapy in Hematologic Malignancies.